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A B S T R A C T
Atrial fibrillation (AF) remains the most common arrhythmia requiring treatment 
in the emergency department and is the cause of major morbidity and considerable 
financial burden. Choosing the appropriate therapy to treat recent-onset AF can be 
extremely demanding and problematic and recent efforts have been focused on iden-
tification of an intravenous antiarrhythmic drug that can provide rapid, effective and 
safe cardioversion of an acute episode. While the currently available antiarrhythmics 
show moderate efficacy and pose a risk for serious ventricular proarrhythmias, ver-
nakalant, a recently developed relatively atrial-selective multi-channel inhibitor, has 
consistently proved to be both effective and safe in converting recent-onset AF to 
normal sinus rhythm (NSR) in randomized clinical trials. Its relatively high atrial se-
lectivity preventing potentially lethal episodes of torsades de pointes (TdP) as well as 
its prompt onset of action, offer intravenous vernakalant a strong advantage over its 
competitors and constitutes an attractive option for the physician.
I N T R O D U C T I O N
Atrial Fibrillation (AF) is the most common sustained arrhythmia in the modern 
era affecting 1–2% of the general population,1 being also the cause of multiple negative 
implications on the health system and the patient itself. Its current prevalence is high 
reflecting the incidence of various contemporary risk factors such as latent hyperten-
sion, alcohol abuse, obesity and sleep apnea2 and is expected to increase considerably 
by 2050, mainly due to the continuously ageing population. Recent epidemiological 
studies report that more than 6 million people in Europe and approximately 3 million 
people in the United States have AF, while these numbers are expected to double dur-
ing the next 30–50 years with a projected prevalence of 7.56 million patients for 2050.3,4
There are multiple mechanisms involved in the pathophysiology of AF. Although 
it is proven that focal triggers, mostly originating in the pulmonary veins, play a sig-
nificant role in the initiation of AF,5 it seems that several classic or newer risk factors 
have a direct impact on atrial myocardium resulting in hypertrophy, fibrosis, apoptosis, 
NEW DRUGS
First Department of Cardiology, 
Evagelismos General Hospital  
of Athens, Athens, Greece
HOSPITAL CHRONICLES 2012, 7(3): 171–181
Correspondence to: 
Antonis S. Manolis, MD,  
First Department of Cardiology, 
Evagelismos Hospital, Athens, 
Greece; E-mail: asm@otenet.gr
Manuscript received March 3, 2012; 
Revised manuscript received May 21, 
2012; Accepted June 1, 2012
KEy WORDS: vernakalant; atrial 
fibrillation; antiarrhythmics; torsades 
de pointes; drug cardioversion
AbbreviAtions
AADs = antiarrhythmic drugs
AHA = American Heart Association
AF = atrial fibrillation
AV = atrio-ventricular 
CABG = coronary artery bypass grafting
ECG = electrocardiogram
EMA = European Medicines Agency
ESC = European Society of Cardiology 
FDA = Food & Drug Administration 
IV = intravenous
NSR = normal sinus rhythm
NYHA = New York Heart Association
TdP = torsades de pointes
Conflict of interest; none declared
172
HOSPITAL CHRONICLES 7(3), 2012
myolysis, dilatation and finally, electrical dissociation between 
atrial muscle bundles.6 Thus, electrophysiological remodeling 
gradually leads to structural remodeling or vice versa that fur-
ther deteriorates atrial ultrastructure subsequently forming a 
vicious cycle and perpetuation of AF,7-9 as the famous Allessie’s 
dictum “AF begets AF” declares.10 These observations outline 
the importance of early medical intervention in the history of 
AF, before electrical remodeling occurs and the arrhythmia 
becomes persistent or permanent.
The shortening of the atrial refractoriness plays a key role 
in electrical remodeling and seems to be the result of multiple 
molecular abnormalities in the atria affecting ion-channels,11,12 
predominantly slow (IKs), rapid (IKr), ultrarapid delayed-rec-
tifier (IKur),13 acetylcholine-regulated (IKACh)14,15 and transient 
outward (Ito) potassium channels as well as sodium channels 
(INa) and cardiac connexins-40 and -43 (Figure 1).16,17 Among 
these, IKur, IKACh and Connexin-40 are only present in the atria, 
offering possible targets for safe antiarrhythmic therapy in the 
future (Table 1). 
TABlE 1. Cardiac ion Currents, the Genes Encoding Them and Their Distribution in Atrial and Ventricular Myocardium. 
Ikur and IK.Ach are Only Present in the Atrial Myocardium
Current Gene Phase of Action Potential Ion Direction Atria Ventricles
INa hH1 0 Inward + +
Ica.L,T SCN5A 2 Inward + +
Ito Kv4.2/4.3 1 Inward + +
IKs KCNQ1 (KvLQT1) 3 Outward + +
IKr KCNH2 (HERG) 2,3 Outward + +
IKur KCNA5 (Kv1.5) 2,3 Outward + -
ICl CTRF/TWIK 2,3 Outward + +
IK1 Kir2 family late 3 & 4 Outward + +
IK.ATP/ACh kir6.2+SUR2a/Kir3 family late 3 & 4 Outward + -
If HCN2/4 4 Inward + +
FIGURE 1. Differences between phases of atrial (a) and ven-
tricular (b) action potential. In the atria, phase 2 has a shorter 
duration than in the ventricles
Although it is widely accepted that AF is a probable cause 
of mortality and severe morbidity,18,19 the strategy of long-term 
normal sinus rhythm (NSR) maintenance has failed to show 
superiority over rate control strategy in a series of randomized 
trials and metaanalyses20-25 excluding the seeming positive out-
come on quality of life.26,27 Possible reasons include “positive 
patient selection” in these studies (low-risk patients), low long-
term maintenance of NSR rate and frequent withdrawal of an-
ticoagulant therapy in the rhythm control groups.4 Moreover, 
proarrhythmia, negative inotropy and extracardiac side effects 
of the currently used antiarrhythmic drugs (AADs) seem to 
play a consistent role in increasing morbidity and mortality. 
However, there is now strong evidence that the aforemen-
tioned neutral effect on hard endpoints is disputable; a clear 
association between NSR maintenance and improved survival 
was evident in an on-treatment analysis of the AFFIRM trial, 
suggesting also that any beneficial antiarrhythmic effects 
of AADs are offset by their adverse effects.28 Moreover, a 
positive outcome on mortality, mainly driven by reduced hos-
pitalizations, was demonstrated after use of dronedarone in 
the ATHENA trial implying that safely maintained NSR may 
prevent cardiovascular events in AF.29 Thus, both recently pub-
lished ESC and AHA guidelines recommend patient-tailored 
therapy dependent on the severity of symptoms attributed to 
AF, how successful rhythm control is expected to be and safety 
issues concerning use of AADs.1,30
Given the fact that currently available AADs show mod-
est efficacy in converting AF and maintaining NSR, while 
at the same time demonstrate serious adverse events,31 it is 
imperative to try to find more effective and much safer drugs 
especially lacking the potential of causing lethal arrhythmias 
like polymorphic ventricular tachycardia in the form of tors-
ades de pointes (TdP). 
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V E R N A K A l A N T
Vernakalant is a recently developed drug that shows several 
attractive characteristics: it is relatively atrial selective result-
ing in minimal ventricular proarrhythmia, while at the same 
time it seems adequately effective in converting new-onset 
AF. Intravenous vernakalant (Brinavess™, MSD, Dublin, 
Ireland) was recently approved by the European Medicines 
Agency (EMA) for the rapid conversion of recent-onset AF 
lasting less than 7 days in nonsurgical patients and less than 3 
days in postoperative AF,32 therefore achieving a last-minute 
inclusion in the 2010 ESC Guidelines for treatment of AF. On 
the contrary, the US Food and Drug Administration (FDA) 
Cardiovascular and Renal Advisory Committee requires more 
safety and efficacy data in order to permit its clinical use in 
the United States.33
P h A R m A C O l O G y
Vernakalant (formerly RSD1235) (Figure 2), a recently 
developed aminocyclohexyl ether, represents a new category 
of AF-converting agents that show preferential action on 
atrial and limited effect on ventricular tissue.34 It is actually 
a multi-ion channel blocker, which inhibits several potas-
sium and sodium currents.35-37 It was discovered more than a 
decade ago after thorough research in a canine model38 and 
its relatively higher effect on prolongation of atrial action 
repolarization and refractory period is attributed to its novel 
feature of inhibition of two certain potassium currents, IKur 
(IC50 = 9μΜ) and IKACh (ΙC50=10μM) that are only present in 
atrial myocardium.39,40 
Vernakalant modestly inhibits Ito, IK.ATP, IKr and late INa cur-
rents, which are expressed in the ventricles as well, rendering its 
characterization as “atrial selective” rather not fully accurate. 
However, it shows higher sensitivity for atria-specific IKur over 
other channels involved in ventricular repolarization, such 
as IKr and INa, a fact that is mainly responsible for its safety.35 
But despite its large pharmacological spectrum of activity and 
its prominent action on atrial-selective potassium currents, 
experimental data suggest that vernakalant’s AF-selective 
actions might be based on state-dependent INa blockade.37,41 It 
seems that vernakalant’s action on late INa current is frequency-
dependent with fast offset kinetics, which means that blockage 
of this current and slowing of atrial conduction is more evident 
at higher atrial rates, making this agent ideal for the treatment 
of rapid AF or other atrial tachyarrythmias.35 In support of 
this notion, recent experimental data using an isolated canine 
atrial model confirmed that in higher rates vernakalant pro-
longs atrial action potential duration significantly more than 
ranolazine or sotalol.42 Moreover, other evidence suggests 
that through late INa current inhibition, vernakalant shows a 
ranolazine-like antiarrhythmic effect suppressing drug-induced 
proarrhythmia from dofetilide, thus having a protective role 
on ventricular myocardium.43 Concerning the risk of TdP, 
balanced competing suppression of these two channels dem-
onstrated in several voltage clamp studies, results in minimal 
effect on QT duration as INa blockade shortens QT and IKr 
blockade prolongs it.44 
P h A R m A C O K I N E T I C S /  D R U G  I N T E R A C T I O N S
Pharmacokinetic and pharmacodynamic data for intra-
venous vernakalant are obtained from four phase II and III 
clinical trials conducted in patients with AF or atrial flutter 
(ACT trials45-48) and two phase I studies in smaller groups of 
healthy volunteers.49,50 Its pharmacokinetic parameters are 
better described by an open two-compartment mammillary 
disposition model, with rapid first-order elimination from the 
central to peripheral compartment. Vernakalant demonstrates 
linear kinetics following a ten-minute injection period;51 its 
metabolism to its major inactive metabolite, RSD1385, is 
predominantly dependent on 4-O-methylation by cytochrome 
P-450 (CYP) 2D6 isoenzyme and only 11% of the drug is se-
creted unchanged in the urine. While average plasma half-life 
is 3.1 hours in men and 2.9 hours in women, it is critically de-
pendent on CYP2D6 activity classifying patients as poor (half-
life 5.6 hours) or extensive metabolizers (half-life 2.2 hours). 
Same differences are observed in the volume of distribution 
measured: 85.84L for those with strong CYP2D6 activity and 
112.50L for those with weak enzyme activity. Nevertheless, the 
average maximum plasma concentration (Cmax) is unaffected 
by CYP2D6 genotype and is 3.29 μg/mL in men and 4.57 μg/
mL in women.52
Most data obtained from the above studies did not show 
age, race, sex, hepatic or renal impairment and heart failure 
to significantly affect vernakalant’s pharmacokinetic proper-
ties. However, the need for dosage adjustments in hepatic FIGURE 2. Molecular structure of Vernakalant.76
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impairment has not been conclusively determined. Although 
there is a lack of formal studies regarding drug interactions 
with vernakalant, there is strong evidence from the ACT I44 
and ACT III46 clinical trials that CYP2D6 inhibitors do not 
affect Cmax and do not seem to cause QT prolongation.53 In 
addition, vernakalant is not highly bound to serum proteins 
and as a result, it is not expected that there would be clinically 
meaningful competition with other highly protein-bound drugs 
such as amiodarone, warfarin, diltiazem and verapamil. 
P h A R m A C O D y N A m I C S
Several pharmacodynamic studies have been performed in 
humans and animals (rabbits, goats and dogs). Vernakalant’s 
ability to prolong the absolute atrial refractory period without 
affecting ventricular repolarization was consistent in all animal 
studies. When goats exposed to 48 hours of pacing-induced 
AF were treated with vernakalant (0.2 mg/kg/h), a significant 
prolongation of the left atrial effective refractory period from 
baseline was evident.54 Even when it was given in higher than 
its usual human therapeutic concentrations, heart rate, mean 
arterial blood pressure and various ECG parameters (PR, RR, 
QT, QRS intervals) were not significantly affected in animals 
with normal heart rhythm. More specifically, there was a very 
mild dose-dependent increase in heart rate from 61 to 70 beats/
min, PR interval from 169 to 184 ms, QRS interval from 88 
to 100 ms and QT interval from 384 to 419 ms. On the con-
trary, in another study, no significant changes were observed 
in vital signs or ECG intervals. Although contradictory data 
were derived from two small Phase I55 and Phase II49 studies 
regarding vernakalant’s effect on atrio-ventricular (AV) nodal 
refractoriness, slight and not statistically significant prolonga-
tion of conduction velocity through AV node and His–Purkinje 
system was seen only at the higher doses. 
As already mentioned, animal studies have shown that 
vernakalant can also have antiarrhythmic effects in the ven-
tricles. Vernakalant significantly decreased the prevalence of 
drug-induced ventricular arrhythmias in animals which had 
drug-induced QT prolongation and this action may be attrib-
uted to late INa current inhibition. 
C l I N I C A l  E F F I C A C y  A N D  S A F E T y
Intravenous (IV) vernakalant’s efficacy in rapidly convert-
ing AF in different clinical settings has been assessed in several 
randomized trials to date. Most of these studies were placebo-
controlled and only one was active-comparator (amiodarone 
used). In addition, one study examined the effectiveness of oral 
vernakalant in maintaining sinus rhythm after cardioversion 
(Table 2). Safety issues were also addressed in the majority 
of them. 
Conversion of Recent Onset Atrial Fibrillation Trial 
(CRAFT) was a phase II, multicenter, double blind, placebo-
controlled, step-dose, randomized study assessing the efficacy 
of IV vernakalant for terminating recent onset AF.36 A total 
of 56 patients with AF continuously present for 3 to 72 hours 
were equally randomized into three groups according to the 
regimen used: placebo, low dose or high dose vernakalant. 
Each group received an initial 10-minute infusion followed by 
a second infusion 30 minutes after completion of first dose, 
if AF still persisted; the low dose regimen was 0.5 mg/kg IV 
and 1 mg/kg IV and the high dose regimen was 3.0 mg/kg IV 
and 2 mg/kg IV for the first and second infusion respectively. 
The primary end point was termination of AF during infusion 
or within 30-min after the last infusion and secondary end 
points included the number of patients in sinus rhythm at 0.5, 
1, and 24 hours post-last infusion and time to conversion. The 
results showed that the high dose of IV vernakalant effectively 
converted 61% of AF cases to sinus rhythm with a median 
time to conversion of 11 min as opposed to placebo and low 
dose regimen (approximately 5%), a statistically significant 
difference. All secondary end points were also in favor of the 
high-dose scheme: patients in sinus rhythm at 30 min (56% 
vs. 5%, p=0.001) and at 1 hour (53% vs. 5%, p=0.0014) and 
median time to conversion (14 vs. 162 min, p=0.016). Concern-
ing safety, there was no significant QRS or QTc prolongation 
and no episodes of TdP or other ventricular arrhythmias were 
observed during the 24 hours of the study. As compared to 
placebo, no significant changes in blood pressure were seen. 
Several patients receiving the high-dose regimen experienced 
a clinically significant decrease in mean heart rate (from 109 
bpm to 90 bpm), possibly attributable to their conversion to 
sinus rhythm. 
Intravenous vernakalant was also evaluated in four studies, 
the Atrial Arrhythmia Conversion Trials (ACT) I, II, III, and 
IV. ACT I was a phase III, randomized, placebo-controlled trial 
designed to test the efficacy and safety of IV vernakalant for 
terminating recent onset atrial fibrillation and atrial flutter.45 
A total of 336 patients with AF or atrial flutter from 3 hours 
to 45 days of duration, were enrolled and then randomized to 
placebo or IV vernakalant at 3 mg/kg as an initial 10-minute 
infusion with a provisional infusion of 2 mg/kg if AF persisted 
after the first dose. All patients were antiarrhythmic- naïve for 
at least 24 hours. Primary end point was conversion of AF to 
sinus rhythm for at least 1 minute within 90 minutes of the start 
of drug infusion in the short-duration AF group. Regarding the 
220 patients with duration of AF between 3 hours and 7 days, 
51% in the vernakalant group were successfully converted to 
sinus rhythm versus 4.0% in the placebo group (P = 0.0001), 
after a median time of 11 minutes. On the contrary, in patients 
with persistent AF (arrhythmia duration more than 7 days), 
no statistically significant difference between the 2 groups was 
seen (P = 0.30). Overall, irrespective of duration of AF, 37.6% 
of patients were cardioverted in the vernakalant group versus 
2.6% in the placebo group (p=0.001). Of the 39 patients with 
atrial flutter, only 1 patient converted to sinus rhythm with 
IV vernakalant, compared with 0 of 15 for placebo patients. 
Like CRAFT, there were no episodes of TdP observed during 
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the 24-hour period following the drug infusion. Interestingly, 
two patients experienced episodes of TdP after this 24-hour 
period but due to the relatively short half-life of the drug (2–3 
hours), authors did not attribute these episodes to vernaka-
lant administration. Investigators also reported four serious 
adverse events that occurred in the vernakalant group, more 
specifically two episodes of severe hypotension, one episode 
of complete atrioventricular block and one episode of cardio-
genic shock. Statistically significant increases in QRS and QTc 
duration were observed in vernakalant-treated patients who 
did not convert from AF.
ACT II46 was a phase III, multicenter, double-blind, 
randomized, placebo-controlled clinical trial conducted in 
patients with new-onset, documented and sustained for 3–72 
hours AF (93%) or atrial flutter (6%) after coronary artery 
bypass graft surgery (CABG) (67%), valvular surgery (24%) 
or both (9%), in order to provide more evidence about the 
efficacy and safety of vernakalant administration. Between 24 
hours and seven days after cardiothoracic surgery, a total of 
190 patients were randomized in a 1:2 ratio to receive either 
placebo or IV vernakalant (3 mg/kg over ten minutes and 
provisional second administration of 2 mg/kg over 10 minutes 
if AF persisted despite the initial infusion). The primary end-
point was conversion to sinus rhythm sustained for at least 1 
minute, within 90 minutes of first exposure to the study drug. 
Cardioversion within 90 minutes occurred in 45% of vernakal-
ant patients (median time to conversion was 12.4 minutes) and 
15% of placebo patients (p=0.0002). An additional infusion 
was needed in only 25% of all patients. Interestingly, none 
of the 6 patients with atrial flutter receiving vernakalant 
experienced cardioversion. Although the study included only 
nine patients with atrial flutter, these data are consistent with 
those derived from ACT I and suggest that vernakalant is not 
effective in new onset atrial flutter. In patients who received 
vernakalant but remained in AF or atrial flutter, a significant 
increase in QRS and QTc intervals was observed, with the lat-
TABlE 2. Clinical Trials Assessing Efficacy of Vernakalant
ClINICAl 
TRIAl
year 
Published
Type of 
Trial N Formulation
Clinical 
Setting
Control 
Group
Primary 
Endpoint
Vernakalant 
vs Control 
(p-Value)
median 
Time to 
Conversion 
(min)
CRAFT
36
2004 RCT/ 
Phase II
56 Intravenous AF duration 
3-72 h
Placebo AF 
termination 
within 30 min
56% vs. 5% 
(p<0.001) 
 14
ACT I
44
2008 RCT/ 
Phase III
220 Intravenous AF duration 
3h-7d
Placebo AF 
termination 
within 90 min
51.7% vs. 4%  
(p<0.001)
11
ACT II
45
2009 RCT/ 
Phase III
150 Intravenous AF post-
cardiac 
surgery
Placebo AF 
termination 
within 90 min
47% vs. 14%  
(p<0.001)
12.4
ACT III
46
2010 RCT/ 
Phase III
265 Intravenous AF duration 
3h-7d
Placebo AF 
termination 
within 90 min
51.2% 
vs. 3.6% 
(p<0.0001) 
8
ACT IV
47
2010 Open label 167 Intravenous AF duration 
3h-7d
- AF 
termination 
within 90 min
Vernakalant: 
50.9% 
14
AVRO
56
2011 RCT 232 Intravenous AF duration 
3-48h
Amiodarone AF 
termination 
within 90 min
53.4% vs. 
5.2%  
(p<0.0001)
11
Torp-Pedersen 
et al 
59
2011 RCT/ 
Phase IIb
605 Oral 150/ 
300/ 500mg 
bid
Non-
permanent 
AF
Placebo Long-term 
sinus rhythm 
maintenance
Vernakalant 
500 mg bid 
better, other 
doses not
-
AF = atrial fibrillation; bid = twice daily; N= number of patients included; RCT = randomized clinical trial.
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ter returning to placebo levels within 2 hours. Vernakalant’s 
small but significant heart rate-lowering effect was no longer 
evident after 90 minutes. Authors reported the occurrence 
of two serious adverse events within 24 hours of vernakalant 
administration, one episode of hypotension and one episode 
of complete atrioventricular block immediately after cardio-
version. Both events were successfully treated. There were no 
cases of TdP, sustained ventricular tachycardia or ventricular 
fibrillation and no deaths.
The ACT III trial47 shared a similar design with ACT I. It 
included 276 patients with AF and atrial flutter from 3 hours to 
45 days of duration and examined the efficacy of IV vernakal-
ant in converting the arrhythmia. For the patients with short 
duration of AF (less than 7 days), 51.2% of the vernakalant 
group were converted to sinus rhythm versus 3.6% of the 
placebo group (p=0.0001), with a median conversion time of 
8 minutes. For the patients whose duration of atrial fibrilla-
tion was between 7 days and 45 days, the efficacy difference 
between the 2 groups was not statistically significant (p=0.33). 
Intravenous vernakalant successfully converted only 7% of the 
patients with atrial flutter (0% for placebo patients) suggesting 
a weak effect of the drug on such context, as the aforemen-
tioned trials have demonstrated. The authors did not report 
any episodes of TdP or ventricular tachycardia. However, one 
vernakalant patient who had severe aortic stenosis and mild 
heart failure (NYHA II) died after experiencing severe hypo-
tension and ventricular fibrillation. This event led to addition 
of a protocol amendment that excluded patients with severe 
valvular stenosis from future studies. Moreover, the authors 
reported a reversible episode of hypotension that led to drug 
discontinuation in a 48-year old man who had NYHA II heart 
failure with an ejection fraction of 25% and a biventricular 
pacemaker implanted.
Pooled data derived from ACT I and ACT III trials were 
used to produce two post-hoc analyses. While for the patients 
with duration of AF between 7 days and 45 days vernakalant 
was not more effective than placebo (p=0.142), when AF dura-
tion was between 3 hours and 7 days, 51.1% of the vernakalant 
treated patients achieved NSR in comparison to 3.8% of the 
placebo group (p = 0.0001).52 A total of 39.8% of the whole 
population was converted after the first infusion of the drug 
(with a median conversion time of 10 minutes), whereas only 
19.7% of the remaining patients finally achieved NSR. How-
ever, 97.2% of successfully converted patients remained in 
NSR after 24 hours. The second analysis of pooled data from 
these two trials focused on the recent-onset AF (>3 and <48 
hours) and its treatment in the emergency department.56 Of 
the 290 patients included, 79% received IV vernakalant and 
59.4% of this group were converted within 90 minutes (the 
median time to conversion was 12 minutes), as compared to 
4.9% of the placebo patients. The authors reported very good 
tolerance and no cases of TdP.
The final Atrial Arrhythmia Conversion Trial published 
so far, ACT IV,48 was an open-label study conducted with the 
objective to further evaluate the safety and efficacy of ver-
nakalant in a larger group of patients. It specifically focused 
on the same population as the previously mentioned post-hoc 
analysis: those with recent-onset AF, lasting >3 hours to ≤7 
days. Patients received the usual 3-mg/kg plus 2-mg/kg dosing 
regimen. The primary efficacy end point was the proportion of 
patients with recent-onset AF who converted to sinus rhythm 
within 90 minutes of the start of the first infusion. Successful 
cardioversion was observed in 51% of the eligible patients 
(N=167), with a median time of 14 minutes. Serious adverse 
events, most commonly bradycardia (2.1%) and hypotension 
(1.7%), leading to drug discontinuation occurred in 4.2% of 
the patients. Although non-sustained ventricular tachycardia 
episodes were reported in 8% of the patients who received 
vernakalant, the majority of them were asymptomatic and oc-
curred 2-24 hours post-dosing. There were no episodes of TdP, 
ventricular fibrillation, or sustained ventricular tachycardia. 
The limited effectiveness of vernakalant in successfully 
converting recent onset atrial flutter was recently confirmed by 
the Steno-2 investigators in a phase II/III randomized, double-
blind, placebo-controlled trial.57 Vernakalant, although well 
tolerated, did not restore sinus rhythm in patients with atrial 
flutter (3% vs. 0% in the placebo group) and only modestly 
increased atrial flutter’s cycle length (average 55 ms) and 
decreased ventricular response rates (-8.2 bpm).
The results of the Active Controlled, Multicenter Study of 
Vernakalant Injection Versus Amiodarone in Subjects with 
Recent Onset Atrial Fibrillation (AVRO) were published in 
2011.58 It was the first double blind randomized study that 
did not use placebo in the control arm. A total of 254 pa-
tients with symptomatic AF (>3 hours and <48 hours) were 
equally randomized to receive either vernakalant (3 mg/kg 
for 10 minutes followed by a 15-minute observation period 
and a second 10-minute infusion of 2 mg/kg) or intravenous 
amiodarone (1 hour loading dose of 5 mg/kg, followed by a 1 
hour maintenance infusion of 50 mg). Primary endpoint of the 
study was the conversion from AF to NSR with a minimum 
duration of 1 minute within 90 minutes of the first exposure 
of the study drug. In AVRO, vernakalant was proven to be 
significantly faster than intravenous amiodarone in convert-
ing AF patients to NSR: conversion rate within 90 minutes 
was 51.7% in patients receiving vernakalant versus 5.2% of 
patients on amiodarone (median time to conversion 11 min-
utes). Moreover, more patients reported no symptoms at 90 
minutes compared with amiodarone. Interestingly, there was 
a higher incidence of atrial flutter within 4-hours post dose in 
the vernakalant group (8.6%) as compared with amiodarone 
(0.9%). Both study drugs were well-tolerated and serious 
events leading to the discontinuation of drugs were uncommon. 
The incidence of hypotension was lower compared with the 
ACT trials. There was an episode of non-sustained monomor-
phic ventricular tachycardia in the vernakalant group that was 
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not associated with QT prolongation. The authors reported 
no cases of TdP, ventricular fibrillation or polymorphic or 
sustained ventricular tachycardia.
Given the limited data available, a specific analysis of the 
ACT trials was conducted to assess the efficacy and safety 
of IV vernakalant for the rapid conversion of AF in patients 
with a history of ischemic heart disease.59 While the efficacy 
analysis included only patients with recent onset AF, the 
safety analysis included all patients with AF or atrial flutter 
receiving vernakalant. Results showed that conversion rate 
was not influenced by the presence of ischemic heart disease. 
Concerning safety, serious adverse events and discontinuations 
due to adverse events were similar in both groups and authors 
reported no cases of TdP, ventricular fibrillation or death in 
patients with ischemic heart disease.
A phase IIIb study in 470 patients with recent onset symp-
tomatic atrial fibrillation, ACT V, was specifically requested 
by the FDA in 2008 in order to further evaluate the safety and 
efficacy of vernakalant versus placebo. ACT V enrollment 
was prematurely suspended following a single serious case of 
cardiogenic shock in a patient who received the drug.
Evidence regarding oral vernakalant and its efficacy in 
maintaining NSR after successful cardioversion are still scarce. 
While the manufacturing company had previously completed 
Phase II testing of oral vernakalant, phase III trials were halted 
from its rights-holder partner company during 2010 and 2011. 
Two phase II studies assessing oral vernakalant’s safety, dos-
ing and efficacy are published up to date. The first one60 was 
a phase IIa study carried out in 159 patients with AF duration 
of >30 and <180 days were randomized into 3 treatment 
groups: placebo twice daily, oral vernakalant 300 mg twice 
daily or 500 mg twice daily. After 3 days of therapy, patients 
remaining in AF were cardioverted with DC shock and con-
tinued their drug treatment for 25 more days. A total of 61% 
of the patients receiving vernakalant maintained NSR at the 
end of the observing period versus 43% of the placebo group 
(p=0.028). Serious adverse events were present in 1% of the 
placebo group, 4% in the 300-mg group, and 6% in the 500-mg 
group. There were no episodes of TdP. The second one60 was 
a phase 2b study that randomized 605 patients to receive oral 
vernakalant 150 mg, 300 mg or 500 mg twice daily or placebo 
for a total period of 90 days. At the end of the treatment time, 
only the 500 mg group reached statistical significance versus 
placebo (p = 0.027). Patients’ hemodynamic tolerance was 
very good, the incidence of serious adverse events was similar 
among the two treatment groups and bradycardia occurred in 
2.7% in the 500-mg group and in 1.1% in each of the other 
groups. There were no episodes of TdP observed. 
The recently updated ESC guidelines for the management 
of AF1 suggest avoiding the use of vernakalant in patients 
with systolic blood pressure less than 100 mm Hg, severe 
aortic stenosis, heart failure (class NYHA III and IV) or 
acute coronary syndromes within the previous 30 days. The 
authors also recommend adequate prehydration to avoid the 
risk of hypotension and ECG and hemodynamic monitoring. 
Finally, it should be noted that although vernakalant seems 
not to significantly prolong the QT interval, patients with 
preexisting QTc prolongation were excluded from participat-
ing in the clinical trials and consequently we should avoid its 
use in this setting. 
D O S I N G  R E G I m E N
The intravenous vernakalant hydrochloride dosing regimen 
approved by the EMA is the one determined in CRAFT trial 
and therefore used in all of the ACT and the AVRO trials: 3 
mg/kg infusion over 10 minutes followed by 2 mg/kg over 10 
minutes administered at 15 minutes later if AF persists.
S I D E  E F F E C T S
Due to relatively short half-life of IV vernakalant (2-3 
hours) all the adverse events recorded in the above mentioned 
phase II and III trials were evaluated within the first 24 hours 
after drug infusion. Findings from CRAFT, ACT I, II, III, IV 
and AVRO trials demonstrated that the side effects mostly 
experienced by patients were dysgeusia (20.4%), sneezing 
(15%), paresthesias (8.8%), nausea (6.5%), cough, pruritus, 
dizziness, hyperhidrosis and hypotension (5.8%).52 Neverthe-
less, all these effects were transient.
V E R N A K A l A N T ’ S  P l A C E  
I N  C U R R E N T  P R A C T I C E
Although a significant proportion of patients with AF 
duration <48 hours seem to spontaneously cardiovert to 
sinus rhythm, the use of an antiarrhythmic agent to promote 
conversion and shorten the length of stay in the emergency 
department is usually preferred. However, currently available 
antiarrrhythmic agents (amiodarone, ibutilide, flecainide, 
propafenone) show several limitations concerning efficacy 
and safety. 
Amiodarone has a relatively slow onset of action and, 
therefore offers little to our efforts to rapidly convert AF in 
the emergency department,62-64 nevertheless, it is the drug 
most commonly used in the acute setting due to safety reasons, 
especially when the clinical background of the patient reveals 
structural heart disease or is unknown. Amiodarone actually 
poses a small risk of proarrhythmia, while at the same time 
it is considered to be the only available drug that is safe for 
use in patients with heart failure and ischemic heart disease, 
a quite common clinical setting in AF patients. These assets 
seem to offset its limited efficacy to promptly convert recent-
onset AF, in the short or medium term. The AVRO trial, as 
already mentioned, showed that IV vernakalant is significantly 
more rapid and effective than amiodarone (52% vs 5% within 
90 minutes post-infusion) while at the same time it is equally 
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safe. However, the quite short 90-minute efficacy period was 
undoubtedly unfair on amiodarone whose conversion rates at 
24 hours are 80-90%, while vernakalant seems to have limited 
benefit in the medium term, with only few patients converted 
beyond the first hour post-infusion.65
Flecainide is a class IC antiarrhythmic agent that has been 
studied for recent-onset AF conversion either in IV formula-
tion (2 mg/kg over 10 min; not available in many countries) 
or in a single 300-mg oral loading dose. Efficacy rates were 
67-92% at 6 hours post-infusion and 57–68% at two to four 
hours and 75–91% at eight hours post-oral dose.66-68 Adverse 
effects observed were conversion to atrial flutter with rapid 
ventricular response, QRS widening, transient hypotension 
and mild neurologic and visual disturbances. Propafenone is 
another IC agent that has been studied in several randomized 
trials. When propafenone was given either as an intravenous 
infusion (not available in many countries) of 2mg/kg over 10 
minutes or as a single 600-mg oral loading dose was found to 
succeed in conversion of recent-onset AF in 41-91% for the 
intravenous drug and 45-94% for the “pill-in-the-pocket” ap-
proach.69 Reported adverse effects were rapid atrial flutter, 
ventricular tachycardia, intraventricular conduction distur-
bances and hypotension. With regard to vernakalant, indirect 
comparison using data from the ACT trials suggests similar 
efficacy to the IC agents, ranging from 51% to 79% for recent-
onset AF. Both flecainide and propafenone are contraindi-
cated in patients with heart failure or structural heart disease 
and ESC guidelines recommend patients should be screened 
for indications and contraindications before implementing 
the ‘pill-in-the pocket’ technique and their efficacy and safety 
should have been previously tested in hospital. Ιntravenous 
ibutilide (up to two infusions of 1 mg over 10 min each, with 
a wait of 10 min between the two doses) is associated with 
a dose dependent efficacy rate of approximately 50% in 90 
minutes with a median time to conversion of 30 minutes (Table 
3).70,71 It is, however, more effective for conversion of atrial 
flutter than AF and moreover, due to significant IKr blockade, 
significantly prolongs QTc carrying thus the important risk of 
serious proarrhythmia and TdP. For that reason, guidelines 
recommend a 6-hour post-infusion ECG monitoring, render-
ing it an unattractive option in the Emergency Department. 
Head to head comparative trials with these antiarrhythmics as 
well as other rate control agents are lacking to better define 
the role of vernakalant in acute AF management.72 Because 
of the fact that in most European countries IV flecainide 
and propafenone are not available, vernakalant is currently 
the only parenteral drug that could offer an alternative to IV 
amiodarone (and less often procainamide) for the treatment 
of recent onset AF, let alone its higher short-term efficacy. 
Indeed, its rapid onset of action and the short median time 
to conversion make vernakalant a possible alternative to the 
more invasive option of electrical cardioversion, especially in 
hemodynamically stable patients.73
Concerning long-term management, since survival benefit 
from rhythm control has been disputed in most clinical tri-
als, recent ESC guidelines suggest that the choice of therapy 
between rate and rhythm control is mostly dependent on 
clinical setting and patients’ preferences. Currently used oral 
TABlE 3. Comparison Between Vernakalant and Ibutilide
Vernakalant Ibutilide
Vaughan-Williams class Not classified Class III
Mechanism of action Prolongation of refractoriness Prolongation of refractoriness
Atrial selectivity Yes No
Effectiveness in acute AF ≈50% converted in 90 min ≈50% converted in 90 min
Effectiveness in acute AFl No Yes
Median Time to conversion  
(min)
11 30
Proarrhythmic effect None or minimal Risk of ventricular proarrhythmia (TdP 1.7% )
Contraindications
SBP <100 mmHg; Severe aortic stenosis;  
Heart failure (NYHA III/IV);  
ACS in the last 30 days; QTc prolongation 
Heart failure (NYHA III/IV); Recent ACS; QTc 
prolongation; Co-administration with class I AADs 
and other QT-prolonging drugs; hypokalemia 
Dosing regimen (IV)
3 mg/kg over 10 min followed by a second infusion  
of 2 mg/kg over 10 min if arrhythmia persists 
1 mg over 10 min followed by a second infusion  
of 1 mg over 10 min if arrhythmia persists 
AADs = antiarrhythmic drugs; ACS = acute coronary syndromes; AF = atrial fibrillation; AFl = atrial flutter; NYHA= New York Heart 
Association; IV = intravenous; TdP= torsades de pointes.
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antiarrhythmics are flecainide, propafenone, sotalol, ami-
odarone and dronedarone but limitations arise, particularly 
concerning safety when dealing with patients with structural 
heart disease. While physicians are surely familiar with the 
serious extracardiac toxicity of amiodarone rendering it the last 
resort, recent safety evidence derived from dronedarone tri-
als, especially ANDROMEDA74 and PALLAS,75 raise doubts 
about its future in AF management. Moreover, the risk of 
TdP with the other antiarrhythmics prevents many clinicians 
from deciding to follow a rhythm control strategy. If we could 
improve the efficacy and minimize the risk of proarrhythmia 
caused by class IA, IC and III antiarrhythmic agents, rhythm 
control could become a more attractive strategy to most clini-
cians than rate control strategy. With data available to-date, 
oral vernakalant appears to have an acceptable efficacy and 
a low risk of TdP but phase III studies are lacking. Given the 
fact that the IV formulation has proved to be safe in patients 
with heart failure76 and ischemic heart disease, manufacturers 
aspire the oral drug to become a reliable alternative to more 
toxic drugs like dronedarone and amiodarone.
C O N C l U S I O N S
Atrial fibrillation is the most commonly treated arrhythmia 
in the emergency department.31 Intravenous vernakalant is a 
novel, relatively atrial-selective antiarrhythmic agent that has 
shown to be efficacious in converting recent onset AF but not 
atrial flutter in several phase III clinical studies. Vernakalant is 
the first in a class of new pharmacologic agents developed for 
the acute conversion of AF and works predominantly by block-
ing early-activating K+ channels and frequency-dependent 
Na+ channels.
Intravenous vernakalant has already been approved in the 
European Union, Iceland, and Norway for the rapid conver-
sion of recent-onset AF to sinus rhythm in adult nonsurgical 
patients with AF duration of seven days or less and post-cardiac 
surgery patients with AF duration of three days or less. How-
ever, the FDA has been reluctant to approve its use due to 
limited safety data, especially after the preliminary termina-
tion of ACT V following the unfortunate outcome in a single 
patient. Although the risk of serious ventricular proarrhythmia 
seems to be minimal, hypotension often observed after its use 
is a concern,77,78 particularly in patients with symptomatic left 
ventricular dysfunction, aortic stenosis and pre-existing low 
blood pressure, situations in which the use of this new drug 
should be avoided. Finally, cost issues will constitute an im-
portant hindrance to expanded use of IV vernakalant. 
Preliminary data on the oral formulation of vernakalant 
have become available but while phase III studies were pending 
to provide more clinical data concerning efficacy and safety, 
in the first quarter of 2012, the drug maker decided to halt 
further development of oral vernakalant. 
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